TERNHIGH SIGNALMANAGEMENT10-K

TERN has entered into a definitive merger agreement with Merck Sharp Dohme LLC, fundamentally altering the company's strategic direction and investor thesis.

The merger agreement represents a complete transformation of TERN's investment profile from a standalone clinical-stage oncology company to an acquisition target. The updated risk factor language emphasizing their lead product candidate TERN-701 and refined focus on oncology (removing previous mentions of obesity programs) suggests the acquisition may be driven by specific pipeline assets rather than the broader platform.

Comparing 2026-03-30 vs 2025-03-20View on EDGAR →
FINANCIAL ANALYSIS

Operating cash flow declined modestly to -$82.2M from -$70.0M in the prior period, reflecting continued investment in clinical development programs typical for a pre-revenue biotech company. The cash burn trajectory appears consistent with clinical-stage operations, though the pending merger will likely make these metrics less relevant for future investment decisions as the company transitions from independent operations to integration within Merck's larger portfolio.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
-17.4%
-$70.0M→-$82.2M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-03-20
ADDED
Unless expressly stated otherwise, the statements contained in this Annual Report on Form 10-K have been prepared as if we were going to remain an independent company.
ii Summary of Principal Risks Associated with Our Business Following our entry into that certain Agreement and Plan of Merger (the Merger Agreement), dated as of March 24, 2026, by and among us, Merck Sharp Dohme LLC (Parent) and Thailand Merger Sub, Inc.
We are a clinical-stage oncology company with a limited operating history and no products approved for commercial sale.
We will require substantial additional funding to finance our operations and achieve our goals.
Failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.
+7 more — sign up free →
REMOVED
ii Summary of Principal Risks Associated with Our Business We are a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale.
We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.
Our business is heavily dependent on the successful development, regulatory approval and commercialization of our current and future product candidates.
Our development programs are focused on product candidates for the treatment of chronic myeloid leukemia, or CML, and obesity.
For one or more of these programs, we may not be able to gain agreement with regulatory authorities regarding an acceptable development plan, the outcome of our clinical trials may not be favorable and, even if favorable, regulatory authorities may not find the results of our clinical trials to be sufficient for marketing approval.
+7 more — sign up free →
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →